Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations denosumab - anti RANKL mAb Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03974100 (CGP24112301) Denosumab BioS Phase 3 522 Percent change from baseline (%CfB) in lumbar spine Bone Mineral Density GP2411 60 mg/mL subcutaneous injection every 6 months ProliaⓇ 60 mg/mL subcutaneous injection every 6 months Postmenopausal women with osteoporosis Target Patients Read-out Milestone(s) 2022 Publication Study data publications expected for 2024 and beyond. The overall study design will be published at WCO and ECTS congresses 2020. 142 Investor Relations | Q4 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation